Immutep Completes Enrolment for Promising INSIGHT-003 Cancer Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2025
0mins
Source: Business Insider
Immutep Ltd Trial Completion: Immutep Limited has completed patient enrolment for its INSIGHT-003 trial, which tests a combination treatment for advanced non-small cell lung cancer, showing promising initial survival outcomes.
Company Overview: Immutep is a clinical-stage biotechnology firm specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, with a current market cap of $325.8 million and a technical sentiment consensus rating of "Sell."
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
